Although nivolumab (Opdivo) and ipilimumab (Yervoy) together demonstrate superior survival in previously untreated patients with advanced melanoma, the combination comes with additional toxicity and an increased price tag, says Jason Luke, MD, assistant professor of Medicine at the University of Chicago Medicine.
MRV Research
Nivolumab Continues to Improve Outcomes in Advanced Melanoma
Anti–PD-1 monoclonal antibodies, such as nivolumab (Opdivo), will become the backbone of advanced melanoma treatment, predicts Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation in Queensland, Australi
Skin cancer researchers carry out ‘world-first’ trials of personalised radiation treatment
World-first melanoma research aimed at developing personalised radiation treatments for skin cancer patients is underway at Brisbane’s Princess Alexandra Hospital.
Twins Study Offers Clues to Genetic Risk of Cancer
A large, new study of identical and fraternal twins in Nordic countries finds that when one twin is diagnosed with any type of cancer, there is a higher than average risk that the other twin will also develop cancer.